Detection and viral RNA shedding of SARS-CoV-2 in respiratory specimens relative to symptom onset among COVID-19 patients in Bavaria, Germany.

Tom Woudenberg1,5*, Ute Eberle2*, Durdica Marosevic1, Bernhard Liebl3,6, Nikolaus Ackermann1,6, Katharina Katz1,6, Andreas Sing1, Bavarian SARS-CoV-2-Group
1 Unit of Infectious Diseases Epidemiology, Bavarian Health and Food Safety Authority
2 Unit of Virology, Bavarian Health and Food Safety Authority
3 State Institute of Health, Bavarian Health and Food Safety Authority, Oberschleißheim, Germany
4 Unit of Public Health Microbiology, Bavarian Health and Food Safety Authority
5 ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
6 Ludwig Maximilians-Universität, Munich, Germany
*Contributed equally
§Senior authors
Bavarian SARS-CoV-2-Group:
Baiker, Armin; Bartha-Dima, Bernadett; Bengs Katja; Berger, Anja; Böhm, Stefanie; Böhmer, Merle; Boll, Kerstin; Carl, Anja; Christian, Jürgen; Dangel, Alexandra; Drdlicek, Juliana; Eisenberger, David; Fingerle, Volker, Gerdes, Lars; Goerlich, Ottmar; Gürtler, Patrick; Hepner, Sabrina; Hobmaier, Bernhard; Höningstamm, Ariane; Huber, Ingrid; Hupfer, Christine; Konrad, Regina; Lupoli, Gaia; Margos, Gabriele; Metz, Jasmin; Mosetter, Michael; Müller, Roswitha; Neubauer-Juric, Antonie; Nickel, Silke; Okeyo, Mercy; Pavlovic, Melanie; Pecoraro, Sven; Schauer, Melanie; Schlenk, Gisela; Schülein, Anika; Schürmann, Eva-Maria; Schulze, Gesine; Scuda, Nelly; Singer, Stefanie; Stellberger, Thorsten; Treis, Bianca; Tuschak, Christian; Valenza, Giuseppe; Wagner, Tobias; Wenning, Mareike; Wimmer, Clara; Zimmermann, Pia

Corresponding author:
Prof. Dr. med. Dr. phil. Andreas Sing, M.A. DTM&H
Facharzt für Mikrobiologie und Infektionsepidemiologie
Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit (LGL)
Tel.: ++49-(0)9131-6808-5814
andreas.sing@lgl.bayern.de

Data availability statement:
The data underlying this article will be shared on reasonable request to the corresponding author.

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Abstract

We assessed SARS-CoV-2 RT-PCR diagnostic sensitivity and Cycle threshold (Ct) values relative to symptom onset in symptomatic COVID-19 patients from Bavaria, Germany, of whom a subset were repeatedly tested. Locally Weighted Scatterplot Smoothing (LOWESS) method was used to assess the relationship between symptom onset and Ct-values. Kaplan Meier plots were used to visualize the empirical probability of detecting viral RNA over time and estimate the time until clearance of viral RNA among the repeatedly tested patients. Among 721 reported COVID-19 cases, the viral RNA was detected in specimens taken between three days before and up to 48 days after symptom onset. Mean Ct-value was 28.6 (95%CI: 28.2 – 29.0) with the lowest mean Ct-values (26.2) observed two days after symptom onset. Up to 7 days after symptom onset, the diagnostic sensitivity of the RT-PCR among repeatedly sampled patients (n = 208) remained above 90% and decreased to 50% at day 12 (95%CI: 10.5 – 21.5).

Our data provide valuable estimates to optimize the timing of sampling of individuals for SARS-CoV-2 detection. A considerable proportion of specimens sampled before symptom onset had Ct-values comparable with Ct-values after symptom onset, suggesting the probability of presymptomatic transmission.

Main text

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected many since the discovery of the virus in January 2020 (1), and has led to significant morbidity and mortality (2). An infection with SARS-CoV-2 leads to various clinical manifestations ranging from asymptomatic infections to severe COVID-19 (3-5). The infection fatality ratio increases with age and underlying medical comorbidities (4, 6).

An infection with SARS-CoV-2 is diagnosed through detection of viral RNA using reverse transcriptase-polymerase chain reaction (RT-PCR) assays (1, 7). The measure of RT-PCR are cycle threshold (Ct) values, where lower Ct-values represent higher viral loads and residual nucleic acid (8). Monitoring Ct-values supplemented by the date of
symptom onset could provide a better picture on RT-PCR diagnostic sensitivity and shedding kinetics of viral RNA over time.

In Bavaria, Germany, first cases of COVID-19 were observed in late January 2020 (9, 10). Initial containment strategy consisted of testing contact persons regardless of symptoms of patients with a lab-confirmed infection of SARS-CoV-2 and returnees from risk areas with respiratory symptoms (11). Contacts were tested for SARS-CoV-2 at the time of identification and 14 days after the last potential date of exposure. All positive patients were retested after a quarantine of 14 days. A positive test after 14 days extended the quarantine up to a negative RT-PCR. The repeated sampling of patients provided the opportunity to assess the diagnostic sensitivity of the RT-PCR relative to the symptom onset. This study aimed to quantify the sensitivity of RT-PCR and the presence of viral RNA through Ct-values relative to symptom onset.

Methods

Notification data

In Germany, COVID-19 is a mandatory notifiable disease. A case was defined as a person with SARS-CoV-2 infection confirmed by RT-PCR. Upon diagnosis, physicians are required to report a case to the local health authorities. For every reported case, local health authorities are requested to complete a questionnaire. This questionnaire covers, among others, demographic characteristics, date of disease onset, date of laboratory confirmation, hospitalization status, probable place of infection, and symptoms. Symptoms that were asked for included fever, coughing, running nose, headache, neck pain, and pneumonia. Case information is subsequently shared with the Bavarian Health and Food Safety Authority through an electronic notification system.

Specimen collection and laboratory confirmation

Initially, in Bavaria, most samples were tested at the Public Health Microbiology (PHM) laboratory of the Bavarian Health and Food Safety Authority (LGL) (7). As the epidemic advanced, additional private, hospital and university laboratories offered SARS-CoV-2 testing. All samples included in this study were tested at the Public Health Microbiology (PHM) laboratory of the Bavarian Health and Food Safety Authority (LGL). RT-PCR procedures at LGL were as follows: Respiratory specimens (nasopharyngeal swabs, sputum, or oral fluid) were obtained from patients and contact persons. Sputum specimens were diluted in 2 mL phosphate buffered saline (PBS).
The following RNA extraction methods were used: QIAamp Bio Robot kit (QIAGEN) on a Hamilton Microlab Star (Hamilton, Bonaduz, Switzerland), RNAdvance Viral Kit on a Biomek i7 (Beckman Coulter, Indianapolis, USA), DNA Extraktion Kit on a m2000sp (Abbott, Chicago, USA), Maxwell 16 LEV Blood DNA Kit on Maxwell Instruments (Promega Fitchburg, USA) and BioSprint 96 One-For-All Vet Kit, IndiMag Pathogen Kit (INDICAL Biosciences, Germany), NucleoMag Vet Kit (Macherey-Nagel, Germany) on KingFisher magnetic particle processors (ThermoFisherScientific, Waltham, USA). In the beginning in-house PCR detection for SARS-CoV-2-RNA was used according to reference (7, 12), followed by the use of the RealStar SARS-CoV-2 RT-PCR Kit RUO (Altona Diagnostics) on the Bio-Rad CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Feldkirchen, Germany), LightCycler 480 (Roche, Basel, Schweiz) or m2000rt System (Abbott, Chicago, USA). The assay detects E-Gene of B-lineage betacoronavirus in FAM and S-Gene specific for SARS-CoV-2 in Cy5. Threshold was manually set within the exponential phase of the detection curve. A specimen was considered positive when (i) both the E gene and the S gene, or (ii) when either the E gene (RealStar) tested positive or the S gene in the Realstar or RdRP with the Corman method tested positive (12). Throughout the article, Ct-values concern Ct-values by using the E-gene target unless stated otherwise.

**Statistical methods**

To combine microbiological data of specimens tested at the Bavarian Health and Food Safety Authority with notification data, we merged records based on the following variables: sex, month and year of birth, reporting municipality, and date of laboratory confirmation. Records with identical variables were included for analyses on the condition that the date of laboratory confirmation was equal to or after date of sampling and date of reporting was equal to or after date of laboratory confirmation. We also excluded records of positive specimens taken five days before symptom onset, as 100% of specimens sampled before five days before symptom onset were measured negative (13).

To assess whether the positivity rate over time is different by age, sex, or reported symptoms, Kaplan Meier plots were used to visualize the empirical distribution of viral RNA detection. The estimated probability is a step function that changes at each event (14). Probabilities were estimated for each additional day since symptom onset, and an event was the first upcoming negative result. Individuals who had no further tests after a positive result were right-censored. To consider that patients reached undetectable levels of viral RNA in between the last positive test and the first negative test, we left-censored the time to a negative test.
We used the Locally Estimated Scatterplot Smoothing (LOESS) method to visualize the relationship between symptom onset and Ct-values. It is a non-parametric method where least squares regression is performed in local subsets. We used R version 3.6.0 to conduct all analyses (15), and we used the R library survival (16) and survminer (17) to produce Kaplan Meier plots and 95% confidence intervals (CI). Reported confidence intervals around the mean Ct-values in the text were estimated using bootstrapping (n = 1000) with R-library Boot. The lower and upper boundary of the confidence intervals were the 2.5th and 97.5 percentiles of the bootstrapped means.

**Results**

For 1306 COVID-19 cases, we identified corresponding records with both epidemiological and microbiological characteristics. Of these, 1300 (99.5%) COVID-19 cases complied with the condition that the date of sampling was before or equal to date of laboratory confirmation and date of notification took place on or before date of laboratory confirmation. For 730 cases, the date of symptom onset was reported. Of these cases, 725 specimens were taken from 3 days before symptom onset until 48 days after symptom onset (Table 1, Figure 1). Four of these cases tested negative for the E-gene but positive for the S-gene. 59 (8.1%) Specimens were taken between three days to one day before symptom onset.

Table 1. Characteristics of 725 patients with SARS-CoV-2 infection reported between January 20 and May 19, 2020 in Bavaria, Germany

| Characteristic       | N (%) or median (IQR) |
|----------------------|-----------------------|
| Age, median (IQR)   | 48 (28 - 62)          |
| 0-18                 | 73 (10)               |
| 19-40                | 195 (27)              |
| 41-65                | 314 (43)              |
| 66-75                | 48 (7)                |
| 76 and above         | 95 (13)               |
| Sex                  |                       |
|                |       |     |
|----------------|-------|-----|
| Male           | 355   | (49)|
| Female         | 370   | (51)|
| Reported symptoms |     |     |
| Unknown        | 2     |     |
| Pneumonia      | 10    | (1)|
| Fever          | 251   | (35)|
| Dyspnea        | 47    | (7)|
| Coughing       | 356   | (49)|
| Running nose   | 136   | (19)|
| Hospitalization |     |     |
| Yes            | 53    | (7)|
| No             | 611   | (84)|
| Unknown        | 61    | (8)|
| Type of specimen |     |     |
| Unspecified upper respiratory swaps | 396 | (55)|
| Nasopharyngeal swaps | 7  | (1)|
| Oral fluid     | 16    | (2)|
| Throat swab    | 306   | (42)|
| Cycle Threshold E-gene, median (IQR) (4 negative) | 28.4 | (24.6 – 32.9)|
| Cycle Threshold S-gene, median (IQR) (47 missing) | 27.7 | (24.0 – 32.1)|
Figure 1. Distribution of day of sampling relative to symptom onset for 724 COVID-19 cases in Bavaria, Germany.

The mean Ct-value among 721 patients was 28.6 (95%CI: 28.2 – 29.0). The mean Ct-value of specimens taken three days before symptom onset was 28.6 (95%CI: 26.1 – 30.7), of specimens taken two days before symptom onset was 26.7 (95%CI: 24.5 – 29.0) and of specimens sampled one day before symptom onset was 26.6 (95%CI: 24.7 – 28.7).

Ct-values depicted by the LOESS curve were lowest among specimens taken close to symptom onset (Figure 2), ranging from -3 to 3 days post symptom onset. From four days after symptom onset and onwards, Ct-values increased (Figure 2).
Figure 2. Ct values (to the E-gene target) of positive specimens shown by days since illness onset (n = 725). The smoothed line was fitted using the LOESS method. Grey area is the 95% confidence interval.

Repeated sampling of COVID-19 patients

We identified 389 individuals who were tested twice including at least one positive specimen. None of these specimens had either a date of sampling after date of laboratory confirmation or a date of laboratory confirmation after date of notification. For 208 patients, date of symptom onset was available (Table 2). Thirty individuals had exclusively positive specimens, 139 started with positive specimens followed by negative specimens, 23 started with negative test result(s) followed by positive specimens only, and 16 individuals had a mixed pattern of positive and negative test results (supplement, Figure 1).
Table 2. Characteristics of 208 patients with SARS-CoV-2 infection who were sampled at least twice. Patients were reported between January 20 and May 19, 2020 in Bavaria, Germany

| Characteristic      | N (%) or median (IQR) |
|---------------------|-----------------------|
| Age, median (IQR)   | 48 (31 - 57)          |
| 0 - 18              | 6 (2)                 |
| 19 – 40             | 74 (36)               |
| 41 – 65             | 98 (47)               |
| 66 – 75             | 6 (2)                 |
| 76 and above        | 24 (12)               |
| Sex                 |                       |
| Male                | 63 (30)               |
| Female              | 145 (70)              |
| Symptoms            |                       |
| Unknown             | 1                     |
| Pneumonia           | 0 (0)                 |
| Fever               | 72 (35)               |
| Dyspnea             | 14 (7)                |
| Coughing            | 110 (52)              |
| Running nose        | 41 (19)               |
| Hospitalization     |                       |
| Yes                 | 9 (4)                 |
| Type of specimen               | Number of tests (n = 553), median (IQR) |
|-------------------------------|--------------------------------------|
| No                            | 186 (89)                             |
| Unknown                       | 13 (6)                               |
| Number of tests (n = 553), median (IQR) | 2 (2 - 3)                             |
| Unspecified upper respiratory| 270 (48)                             |
| nasopharyngeal                | 6 (1)                                |
| Oral fluid                    | 20 (4)                               |
| Throat swab                   | 253 (45)                             |
| Sputum                        | 4 (1)                                |

The median days post symptom onset to a negative RT-PCR was 12.5 (95%CI: 10.5 – 21.5, Figure 3). Ten per cent tested negative after 7.5 days (95%CI: 0.5 – 12.5), 25 per cent after 10.5 days (95%CI: 7.5 – 17), 75% after 21.5 days (95%CI: 12.5 - 28), and 95% after 39 days (95%CI: 30.5 - 43.5). The median time to a negative RT-PCR test was comparable between males (12.5, 95%CI: 9.5 – 28.5) and females (12.5, 95%CI: 10.5 – 21.5) and patients with (13.5, 95%CI: 9.5 – 30.5) or without fever (12.5, 95%CI: 10.5 – 21.5, Figure 4). The median time to a negative test of patients older than 65 was longer (17.0, 95%CI: 13.5 – 33.5) than patients below 19 (10.5, 95%CI: 10.5 – 43.5+) and between 19 and 65 (12.5, 95%CI: 10.5 – 21.5), but these estimates should be carefully interpreted given the wide confidence intervals. A Kaplan Meier plot with the number of patients reported in the estimation of the probability of testing positive is provided as supplementary material (Figure S2).
Figure 3. Time until the loss of SARS-CoV-2 RNA detection after symptom onset among 208 patients tested at least twice in Bavaria, Germany. The red line and red-shaded area depict the empirical distribution of persistence of positive tests and 95% confidence interval, respectively.

Figure 4. Time until the loss of SARS-CoV-2 RNA detection after symptom onset among 208 patients tested at least twice in Bavaria, Germany stratified by sex (A), age (B), and reported fever (C).
Discussion

In our study, we aimed to describe the diagnostic sensitivity of RT-PCR and Ct-values of SARS-CoV-2 relative to the symptom onset in symptomatic COVID-19 cases reported in Bavaria, Germany. As all contact persons of patients with COVID-19 were tested regardless of the presence of symptoms, many infections were detected prior to symptom onset (8%) and most COVID-19 cases concerned non-hospitalized cases (84%). Ct-values were lowest, hence highest in viral load, close to symptom onset, with higher Ct-values from four days post symptom onset and onwards. This underlines the possibility of transmission and infection occurring prior to symptom onset as described elsewhere (9, 18).

In a subset of repeatedly sampled patients, we found that specimens taken up to 7 days post symptom onset had a 90% chance to test positive, this remained 75% up to 10.5 days and reduced to 50% with 12.5 days. The mean median duration of viral RNA shedding was found to be 17 days in upper respiratory specimens from 43 studies (19). The majority of these studies were testing hospitalized patients, which could explain the longer shedding time compared with our estimate as only 16% of notified COVID-19 cases in our sample had been hospitalized. Another explanation could be due to the use of different methods either incorporating or not incorporating the time between the last positive and first negative test. As the time between sampling was considerable (Figure S1) due to a testing policy which consisted of testing contact persons upon identification and after 14 days, we took into account the time between the last positive test and the first negative test. Without this correction (i.e. left-censoring), the median duration until a negative test was 22 days (95%CI: 21-23). This estimate resembles three other estimates ranging from 19 to 23 days derived with the Kaplan-Meier method (20-22). With a sharp decrease from around 7-10 days post symptom onset, one could consider complementing diagnosis by using serology to detect a (past) infection, as the sensitivity of detecting antibodies (IgM and IgG) increases (23). Eleven days post symptom onset, the sensitivity of antibody testing was estimated to be more than 80% (IgG) (23). In another study, serology, measuring total outperformed RT-PCR after seven days (24), and in another study measuring IgM even after 5.5 days (25).

Positive specimens were found up to 3 days before symptom onset. A limitation of our study is that we cannot assess the denominator, i.e. the total number of infected people who were tested three days before symptom onset. Kucirka et al. have estimated that 68% of specimens taken one day before symptom onset were falsely
negative (13). Given that the incubation period is estimated to be around 4-6 days (10, 26), it should be considered to not sample a contact person 1-2 days after exposure to avoid false-negative test results.

Compared with other studies assessing sensitivity and Ct-values (19), the majority of our cases were in non-hospitalized patients. As the majority of COVID-19 cases are mild cases who do not require hospitalization (5, 27), our study provides a necessary insight into the sensitivity and viral RNA shedding of milder COVID-19 cases. We obtained these estimates by combining laboratory data on the date of sampling and Ct-values, with notification data on symptoms and symptom onset. In theory, it could be that specimens were matched to the wrong records in the notification data. However, we combined records based on identical values for four variables. Subsequently, only a few records were excluded based on contradictory timing of date of laboratory confirmation and date of notification. Therefore, we believe that the number of specimens that were matched to a different patient remained very low and can be considered negligible on our estimates.

Our data concern Ct-values, and we did not examine the relationship with propagating virus from samples and their Ct-values. An assessment of the infectiousness of these samples was therefore not possible. However, we expect that higher Ct-values are associated with a higher probability of isolating virus in culture (28, 29, 30, 31, 32). Finally, we assessed the Ct-values using several RNA extraction methods, different PCR platforms, and PCR detection systems. Furthermore, specimens have been sampled in different ways.

In conclusion, the probability of detecting viral RNA in respiratory samples in symptomatic COVID-19 patients is highest close to symptom onset and reduced considerably 10 days after symptom onset. The lowest Ct-values of SARS-CoV-2 were found around symptom onset up to three days past symptom onset as depicted by the LOESS curve. Similar Ct values were found 1-3 days before symptom onset and suggest the potential pre-symptomatic transmission. Our findings underline the importance of early identification of contact persons to implement timely quarantine, and careful timing of sampling to prevent false negatives test results.
References

1. Zhu N et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine.

2. World Health Organisation. COVID-19 Weekly Epidemiological Update: WHO; 9 March 2021. (Weekly epidemiological update – 9 March 2021).

3. Richardson S et al. (2020) Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 323(20):2052-9.

4. Russell TW et al. (2020) Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Eurosurveillance 25(12):2000256.

5. Streeck H et al. (2020) Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nature Communications; 11(1): 5829.

6. Salje H et al. (2020) Estimating the burden of SARS-CoV-2 in France. Science

7. Konrad R et al. (2020) Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020. Eurosurveillance 25(9):2000173.

8. Binnicker MJ. (2020) Can the SARS-CoV-2 PCR Cycle Threshold Value and Time from Symptom Onset to Testing Predict Infectivity? Clinical Infectious Diseases.

9. Böhmer MM et al. (2020) Outbreak of COVID-19 in Germany resulting from a single travel-associated primary case.

10. Böhm S et al. (2021) Epidemiology and transmission characteristics of early COVID-19 cases, 20 January–19 March 2020, in Bavaria, Germany. Epidemiology and Infection; 149: e65. doi: 10.1017/S0950268821000510.

11. Robert Koch Institute. [COVID-19: Clarification of suspicions and measures - Orientation guide for doctors] Berlin: RKI; 2020 [Available from: https://edoc.rki.de/handle/176904/6484.6?locale-attribute=en].
12. Corman VM et al. (2020) Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* 25(3):2000045.

13. Kucirka LM et al. (2020) Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. *Annals of Internal Medicine*.

14. Clark TG et al. (2003) Survival analysis part I: basic concepts and first analyses. *British Journal of Cancer* 89(2):232-8.

15. Team RC. (2013) R: A language and environment for statistical computing.

16. Therneau TM, Lumley T. (2014) Package ‘survival’. Survival analysis Published on CRAN 2:3.

17. Kassambara A et al. (2017) Package ‘survminer’. Drawing Survival Curves using ‘ggplot2’ (R package version 0.3.1).

18. Arons MM et al. (2020) Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. *New England Journal of Medicine*.

19. Cevik M et al. (2021) SARS-CoV-2 viral load dynamics, duration of viral shedding and infectiousness: a systematic review and meta-analysis. *Lancet Microbe*; 2:e13-22

20. Wang K et al. (2020) Differences of SARS-CoV-2 Shedding Duration in Sputum and Nasopharyngeal Swab Specimens Among Adult Inpatients With COVID-19. *Chest*.

21. Fu Y et al. (2020) Risk Factors for Viral RNA Shedding in COVID-19 Patients. *European Respiratory Journal*.

22. Yan D et al. (2020) Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. *European Respiratory Journal*.

23. Long Q-X et al. (2020) Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine* 1-4.

24. Lou B et al. (2020) Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. *European Respiratory Journal*.

25. Guo L et al. (2020) Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). *Clinical Infectious Diseases*.
26. **Linton NM et al.** (2020) Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. *Journal of clinical medicine* 9(2):538.

27. **Mizumoto K et al.** (2020) Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan. *Euro Surveill* 25(10).

28. **Bullard J et al.** (2020) Predicting infectious SARS-CoV-2 from diagnostic samples. *Clinical Infectious Diseases*.

29. **Woelfel R et al.** (2020) Virological assessment of hospitalized patients with COVID-2019. *Nature*. 581(7809): 465-469.

30. **Singanayagam A et al.** (2020) Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. *Eurosurveillance* 25(32):2001483.

31. **La Scola B et al.** (2020) Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology* 39(6):1059-61.

32. **Van Kampen JJA et al.** (2021) Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nature Communications*; 12(1):267

Downloaded from https://www.cambridge.org/core, IP address: 207.241.227.105, on 29 Jun 2021 at 19:59:31, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268821001345